SeeThruEquity Issues Update on Progressive Care, I
Post# of 1525
(Total Views: 721)
Posted On: 03/09/2018 12:09:00 PM
SeeThruEquity Issues Update on Progressive Care, Inc.
https://ih.advfn.com/p.php?pid=nmona&article=76910144
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Progressive Care, Inc. (OTCQB: RXMD).
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care" is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long-term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
Highlights from the update include:
Progressive Care has taken significant strides since the last update
issued by SeeThruEquity on the company, with the business eclipsing $20mn
in revenues in 2017 and several new initiatives intended to drive growth
and improve operations in the future. Highlights include:
Increasing price target to $0.35 for RXMD
We are increasing our price target for RXMD at this time to $0.35 per share. Shares eclipsed our prior target of $0.10, as the company has continued to grow and execute in a challenging and competitive environment since our last update, with 2016 revenues of $18.3mn and 2017 revenues confirmed at above $20mn by the company in January. In the interim, the company has achieved multiple corporate objectives, including an uplisting to the OTCQB and the resumption of plans to expand its pharmacy operations to additional states. We see RXMD as an attractive growth story in the healthcare sector applying an innovative approach to the pharmacy business. It is also worth pointing out that healthcare and related companies offer some shielding against factors affecting the broader markets - given the important role of regulation and industry-specific. We would think this would be true for RXMD as well, if it is able to continue to execute on its business objectives and show continued growth.
https://ih.advfn.com/p.php?pid=nmona&article=76910144
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Progressive Care, Inc. (OTCQB: RXMD).
Progressive Care, Inc. (OTCQB: RXMD, "Progressive Care" is a health services and technology company based in Miami, FL. Through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, the company provides a range of health services including administration and practice management, utilization management, quality assurance, Electronic Health Records (HER) EHR implementation, billing and coding, health practice risk management, prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long-term care facilities. The company also provides tele-pharmacy services under the name Tele-Pharmco.
Highlights from the update include:
Progressive Care has taken significant strides since the last update
issued by SeeThruEquity on the company, with the business eclipsing $20mn
in revenues in 2017 and several new initiatives intended to drive growth
and improve operations in the future. Highlights include:
Increasing price target to $0.35 for RXMD
We are increasing our price target for RXMD at this time to $0.35 per share. Shares eclipsed our prior target of $0.10, as the company has continued to grow and execute in a challenging and competitive environment since our last update, with 2016 revenues of $18.3mn and 2017 revenues confirmed at above $20mn by the company in January. In the interim, the company has achieved multiple corporate objectives, including an uplisting to the OTCQB and the resumption of plans to expand its pharmacy operations to additional states. We see RXMD as an attractive growth story in the healthcare sector applying an innovative approach to the pharmacy business. It is also worth pointing out that healthcare and related companies offer some shielding against factors affecting the broader markets - given the important role of regulation and industry-specific. We would think this would be true for RXMD as well, if it is able to continue to execute on its business objectives and show continued growth.
(0)
(0)